Chris comes to MH Clear after spending 28 years in the pharmaceutical industry. During this time, he spent the first 21 years working for Johnson & Johnson’s oncology company, Ortho Biotech, which eventually became Janssen Oncology. During his tenure, he held numerous positions giving him expertise in Sales, Sales Training and Development, Sales Management, Contracting, Market Access, Reimbursement, and Key Account Management. +In 2017, Chris was recruited away from Johnson & Johnson to launch AstraZeneca’s first Hematology Franchise. Within nine months he was quickly promoted to the Commercial Business Director role, heading up sales for the western half of the United States. Over the next 6 years, he built strong relationships with key customers, while his team led the Hematology portfolio to blockbuster status. His goal is to make mental health screening for patients a standard of care and believes a patient with a stable mindset can be more adherent to the treatment plan leading to better outcomes. Chris also believes MH Clear’s mental health data will be the first of its kind and will reveal trends and insights to help shape the way patients are treated.